Potential utility of amantadine DR/ER in persons with Parkinson’s disease meeting 5-2-1 criteria for device aided therapy

BACKGROUND: The 5-2-1 criteria (≥5 levodopa doses/day, ≥2 h OFF/day, and ≥ 1-hour dyskinesia/day) propose to identify people with Parkinson’s disease (PD) who are poorly controlled on oral therapies and who may therefore benefit from device-aided therapies. Amantadine-DR/ER is the only medication FD...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Robert A., Goud, Santosh, Formella, Andrea E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760552/
https://www.ncbi.nlm.nih.gov/pubmed/35059622
http://dx.doi.org/10.1016/j.prdoa.2021.100123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760552/
https://www.ncbi.nlm.nih.gov/pubmed/35059622
http://dx.doi.org/10.1016/j.prdoa.2021.100123

Ejemplares similares